Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to assess the safety and tolerability of inhaled nitric
oxide (NO) when administered by nasal cannula over a 44 hour period to clinically stable
Cystic Fibrosis (CF) subjects. Toxicity is to be defined as a drop in oxygen saturations, a
decline in forced expiratory volume in one second (FEV1), or an increase in methemoglobin.